Using 3D printing to enhance nasal irrigation for chronic rhinosinusitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research utilizes three-dimensional (3D) printing technology to create personalized models of patients' nasal anatomy, aiming to improve the effectiveness of nasal irrigation treatments for chronic rhinosinusitis. By providing a hand-held device that helps patients understand their unique nasal structure, the study seeks to enhance irrigation techniques and ultimately improve patient satisfaction and quality of life. The focus is on patients who are not candidates for surgery or prefer less invasive treatment options. The study will evaluate the impact of these personalized models on treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Chronic rhinosinusitis without nasal polyps (CRSsNP) or Chronic rhinosinusitis with nasal polyps (CRSwNP).

Exclusion Criteria:

* Patients with significant nasal polyps (as determined by a clinician) were excluded upfront due to the unlikeness of irrigation penetration regardless of the head position. Patients with significant atopy, cystic fibrosis, granulomatosis with polyangiitis or other connective tissue disorder, and current pregnancy were also excluded.

Where it's running

• The Ohio State University Eye and Ear Institue
  Columbus, Ohio, United States Recruiting

Study contacts

• Study coordinator: Kai Zhao, PhD
• Email: zhao.1949@osu.edu
• Phone: 2673032322

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sinonasal microbiome transplant for chronic rhinosinusitis

  This will try a sinonasal microbiome transplant to see if it reduces symptoms in people with chronic rhinosinusitis with or without nasal polyps.

  Recruiting Phase 2/3 Region Skane · Helsingborg · NCT07184684

• Investigating the effects of Dupilumab on nasal barrier function in chronic rhinosinusitis patients

  This study is testing if the medication Dupilumab can improve the nasal barrier function in people with chronic rhinosinusitis, especially those with nasal polyps.

  Recruiting Medical University of Vienna · Vienna, Austria · NCT06398873

• Mepolizumab with or without in-office nasal polypectomy for chronic rhinosinusitis with nasal polyps

  This study tests whether adding mepolizumab, alone or with in-office nasal polypectomy, helps adults with chronic rhinosinusitis with nasal polyps who need biologic treatment.

  Recruiting at 7 sites Phase 4 Instituto de Investigación Marqués de Valdecilla · Barakaldo and 6 other locations · NCT07814924

• Tezepelumab for Chinese adults with nasal polyps: a 24-week treatment study

  This trial tests whether tezepelumab can improve nasal polyps and symptoms in Chinese adults with chronic rhinosinusitis with nasal polyps who are starting therapy.

  Recruiting at 34 sites Phase 3 AstraZeneca · Beijing and 33 other locations · NCT07520162

• Reducing how often biologic injections are given for chronic nasal polyps

  This study will test whether spacing out mepolizumab or dupilumab injections to every 6–8 weeks keeps symptoms controlled in adults with partly controlled chronic rhinosinusitis with nasal polyps.

  Recruiting at 3 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Aalborg and 8 other locations · NCT07187583

• SHR-1905 injection for chronic rhinosinusitis with nasal polyps

  This trial will test whether SHR-1905 injections help adults with chronic rhinosinusitis with nasal polyps reduce polyp size and symptoms compared with placebo.

  Recruiting Phase 3 Guangdong Hengrui Pharmaceutical Co., Ltd · Shanghai, Shanghai Municipality · NCT07132827

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.